表皮生长因子受体抑制剂
乙酰化
表皮生长因子受体
串扰
内吞作用
癌症
内化
药效团
ERBB3型
抗药性
医学
癌症研究
生物信息学
药理学
生物
受体
内科学
基因
生物化学
光学
物理
微生物学
作者
Manvendra Kumar,Gaurav Joshi,Joydeep Chatterjee,Raj Kumar
标识
DOI:10.2174/1568026620666200207100227
摘要
Background: The EGFR is overexpressed in numerous cancers. So, it becomes one of the most favorable drug targets. Single-acting EGFR inhibitors on prolong use induce resistance and side effects. Inhibition of EGFR and/or its interacting proteins by dual/combined/multitargeted therapies can deliver more efficacious drugs with less or no resistance. Objective: The review delves deeper to cover the aspects of EGFR mediated endocytosis, leading to its trafficking, internalization, and crosstalk(s) with HDACs. Methods and Results: This review is put forth to congregate relevant literature evidenced on EGFR, its impact on cancer prognosis, inhibitors, and its trafficking regulation by acetylation along with the current strategies involved in targeting these proteins (EGFR and HDACs) successfully by involving dual/hybrid/combination chemotherapy. Conclusion: The current information on cross-talk of EGFR and HDACs would likely assist researchers in designing and developing dual or multitargeted inhibitors through combining the required pharmacophores.
科研通智能强力驱动
Strongly Powered by AbleSci AI